CARLSBAD, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Genoptix, Inc. , a provider of personalized diagnostic services, announced today that it expects to report its financial results for the fourth quarter and full-year 2008 after closing of the NASDAQ Global Market on Thursday, February 26, 2009.
A conference call hosted by President and CEO, Dr. Tina S. Nova, and other members of senior management will take place on the same day at 2:00pm PST (5:00pm EST) and will be webcast live on the Genoptix website.
To access the live conference call via phone, dial 800-295-3991 in the U.S. or Canada and 617-614-3924 for international callers. Please specify to the operator that you would like to join the “Genoptix Fourth Quarter and Full-Year 2008 Earnings Conference Call.” The participant code for the call is 82029062. If you are unable to listen to the live webcast, a replay of the call will be available through Thursday, March 5, 2009. Interested parties can access the rebroadcast by dialing 1-888-286-8010 or 1-617-801-6888 internationally and entering the reservation number 30354059.
The conference call will be webcast live on the Internet and is accessible through the investor relations section of the Genoptix website at www.genoptix.com, or by accessing the external website, www.fulldisclosure.com. To participate in the webcast, please connect to the Genoptix website several minutes prior to the start time to register, download and install any necessary software that may be required. An online replay is planned to follow shortly after and will be available until Thursday, March 26, 2009.
About Genoptix, Inc.
Genoptix is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists. Genoptix’s highly trained hematopathologists utilize sophisticated technology to provide integrated testing and actionable diagnostic reports. Its diagnostic services are designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma. Founded in 1999, Genoptix completed its initial public offering in November 2007 and has been profitable since the first quarter of that year.
Any statements in this press release or that may be made on the Genoptix conference call about expectations, beliefs, plans, objectives, assumptions or future events, or future performance are not historical facts and are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. For information about risks and uncertainties that Genoptix faces, please refer to the “Risk Factors” section in the Company’s most recent Quarterly Report on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission. Genoptix assumes no obligation and expressly disclaims any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
CONTACT: Marcy Graham, Sr. Director, Investor Relations of Genoptix, Inc.,
+1-760-930-7150, investorrelations@genoptix.com; or Joleen Schultz,
Principal of Mentus, +1-858-455-5500, ext. 215, jschultz@mentus.com, for
Genoptix, Inc.
Web site: http://www.genoptix.com/
